Elsevier

International Journal of Cardiology

Volume 201, 15 December 2015, Pages 247-252
International Journal of Cardiology

Safety and efficacy of ezetimibe: A meta-analysis

https://doi.org/10.1016/j.ijcard.2015.08.103Get rights and content

Abstract

Background

The addition of ezetimibe to statin therapy has been widely demonstrated to significantly reduce low-density lipoprotein cholesterol levels. However, the efficacy of ezetimibe in reducing CV events and its safety has been less investigated. The aim of the current meta-analysis was to report efficacy and safety of ezetimibe from randomized clinical trials.

Methods

Randomized clinical trials with a follow-up of at least 24 weeks, enrolling more than 200 patients, comparing ezetimibe versus placebo or ezetimibe plus another hypolipidemic agent versus the same hypolipidemic drug alone and reporting at least one event among all-cause and CV mortality, myocardial infarction (MI), stroke and new onset of cancer were included in the analysis.

Results

7 trials enrolling 31,048 patients (median follow-up 34.1 ± 26.3 months; 70% women; mean age 61 ± 8 years) were included in the analysis. Compared to control therapy, ezetimibe significantly reduced the risk of MI by 13.5% (RR: 0.865, 95% CI: 0.801 to 0.934, p < 0.001) and the risk of any stroke by 16.0% (RR: 0.840, 95% CI: 0.744 to 0.949, p = 0.005), without any effect on all-cause and CV mortality (RR: 1.003, 95% CI: 0.954 to 1.055, p = 0.908; RR: 0.958, 95% CI: 0.879 to 1.044, p = 0.330; respectively) and risk of new cancer (RR: 1.040, 95% CI: 0.965 to 1.120, p = 0.303).

Conclusions

Ezetimibe significantly reduces the risk of MI and stroke without any effect on all-cause and CV mortality and risk of cancer.

Introduction

Statins (3 HMG-coA inhibitors) have been proven to reduce cholesterol levels and cardiovascular (CV) events in primary and secondary prevention [1], [2], [3], [4]. Subsequent studies have shown that intensive statin therapy, as compared with less intensive statin therapy, reduces low-density lipoprotein cholesterol (LDL-C) further and produces a greater reduction in CV events [5], [6], [7], [8], [9]. However, there is a significant risk of recurrent CV events even in patients receiving high dose statins, the use of which has also raised safety concerns, leading to the search of additional lipid-modifying therapies [10], [11], [12], [13], [14].

Circulating cholesterol originates from liver synthesis and intestinal absorption, with the latter mechanism increasing its contribution during treatment with statins [15], [16]. Ezetimibe markedly reduces the intestinal absorption of cholesterol interacting with the Niemann–Pick C1-Like 1 (NPC1L1) protein [17], [18]. This results in a further 20–25% reduction in LDL-C levels among patients treated with statins [19], [20]. Should the relationship between LDL-C reduction and cardiovascular events reduction shown by the CTT collaborative study hold true also for ezetimibe [4], this would translate into an additional clinical benefit.

However, a widespread use of ezetimibe has been hindered by the recommendation of the ACC/AHA guidelines to base treatment on statins, in the absence of efficacy data for ezetimibe [21] and by concerns over the safety of this agent, notably over the possibility of an increased incidence of cancer. This originated from the finding of an increased incidence of cancer among patients taking ezetimibe/simvastatin as compared with placebo in the SEAS trial, designed to evaluate the effect of the combination on the progression of aortic stenosis [22]. The publication of a specifically designed safety analysis including data from ongoing trials was not unanimously accepted as appropriate and reassuring [23], leading to a strong controversy [24], [25]. This must not have been completely solved, as suggested by the conclusions on the risk/benefit ratio of ezetimibe reached by a recent meta-analysis published [26]. Notably, this analysis did not include data from the IMPROVE-IT trial [27], [28], [29], [30]. Since this latter trial followed patients for an average of six years providing more than 100,000 patient-year of safety data, approximately the same amount of the combined data included, we thought it would be important to reassess the safety and efficacy of ezetimibe including this essential information.

Section snippets

Search strategy

This study was designed according to the PRISMA (Preferred Reporting Items for Systematic reviews and meta-analyses) statement [31]. MEDLINE, Cochrane Database, ISI Web of Sciences and SCOPUS were searched for articles published in English and other languages until June 2015. Studies were identified by the following headings: ezetimibe, random, randomized controlled trial, and clinical trial. We used reference lists of the retrieved articles and reviews about the current topic as well

Characteristics of included trials

Of 3037 papers identified in the initial search, 167 were retrieved for more detailed evaluation. 160 studies were subsequently excluded. Therefore, 7 trials [22], [30], [38], [39], [40], [41], [42] were finally included in the analysis, which enrolled 31,048 patients (70% males; mean age 61 ± 8 years; mean follow-up 34.1 ± 26.3 months), 15,586 of which were assigned to ezetimibe and 15,462 patients to control therapy (Fig. 1). Baseline characteristics of 7 trials included in the meta-analysis are

Discussion

The findings of the current meta-analysis indicate that ezetimibe significantly reduces the risk of MI and stroke without any significant effect on overall and CV mortality and risk of cancer.

A recent meta-analysis including 7 randomized clinical trials showed a non-significant effect of ezetimibe added to statin on all-cause or CV death, MI, stroke and cancer, suggesting lack of clinical benefit associated with the use of ezetimibe [26]. However, in this analysis SHARP and SEAS trials [22],

Conclusions

Ezetimibe significantly reduces the risk of MI and stroke without any effect on all-cause and CV mortality and risk of cancer.

Conflicts of interest

GdF and PPF received honoraria from Merck Sharp & Dhome for consultant activity and GdF is member of the IMPROVE IT Steering Committee.

Funding

None.

References (43)

  • C. Baigent et al.

    The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

    Lancet

    (2011)
  • M. Landray et al.

    The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD

    Am. J. Kidney Dis.

    (2006)
  • Heart Protection Study Collaborative Group

    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial

    Lancet

    (2002)
  • C. Baigent et al.

    Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

    Lancet

    (2005)
  • Cholesterol Treatment Trialists C et al.

    Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

    Lancet

    (2010)
  • C.P. Cannon et al.

    Intensive versus moderate lipid lowering with statins after acute coronary syndromes

    N. Engl. J. Med.

    (2004)
  • J.A. de Lemos et al.

    Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

    JAMA

    (2004)
  • J.C. LaRosa et al.

    Intensive lipid lowering with atorvastatin in patients with stable coronary disease

    N. Engl. J. Med.

    (2005)
  • T.R. Pedersen et al.

    High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

    JAMA

    (2005)
  • D. Preiss et al.

    Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

    JAMA

    (2011)
  • The ACCORD Study Group

    Effects of combination lipid therapy in type 2 diabetes mellitus

    N. Engl. J. Med.

    (2010)
  • Cited by (0)

    1

    Equal contribution.

    View full text